Commercial ApprovalElfabrio remains favorable with commercial approval across 23 territories globally for the treatment of Fabry disease.
Debt And Capital StructureCapital structure now looks exceptionally clean, with no remaining long-term debt outstanding.
Market Opportunity And Revenue PotentialProtalix management indicated that the total Fabry disease market opportunity may raise to $3.1B by 2030, with the potential for the royalty stream from Elfabrio to reach $120-150M per year to the company.